StemCyte, Inc.
BiotechStemCyte, Inc. is a biotechnology company with 1 FDA-approved products.
StemCyte, Inc.'s Key Drugs
StemCyte, Inc.'s core commercial portfolio centers on regenecyte — its most strategically important drugs approved in the last 15 years.
StemCyte, Inc.'s Recent FDA Approvals
StemCyte, Inc. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
StemCyte, Inc.'s Therapeutic Areas
Disease areas where StemCyte, Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
StemCyte, Inc. Pipeline Snapshot
Active clinical trials for StemCyte, Inc. across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • regenecyte leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-11-20
- Latest
- 2024-11-20
- Applications
- 1